Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 1/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 6/20 | 0.36 |
| ▸ | HTR2B | P41595 | 4/20 | 0.36 |
| ▸ | PNMT | P11086 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5776030 | 0.82 | CD44 (0.44) | CD44CD274HRH3HTR2CHTR2B | |
| SCHEMBL17585072 | 0.78 | CD44 (0.49) | CD44HRH3HTR2CHTR2BPNMT | |
| Hydrochloric Acid SCHEMBL17583922 | 0.77 | CD44 (0.47) | CD44HRH3HTR2CHTR2BPNMT | |
| SCHEMBL5774902 | 0.75 | CPT2 (0.45) | — | |
| SCHEMBL8177228 | 0.73 | CD44 (0.43) | CD44CD274HRH3PNMT | |
| SCHEMBL2358135 | 0.73 | PNMT (0.56) | CD44CD274HTR2CHTR2BPNMT | |
| SCHEMBL31233660 | 0.73 | PNMT (0.56) | CD44CD274HTR2CHTR2BPNMT | |
| SCHEMBL4716663 | 0.72 | CD44 (0.45) | CD44CD274HTR2CHTR2BPNMT | |
| Hydrochloric Acid SCHEMBL1124611 | 0.71 | PNMT (0.55) | CD44CD274HTR2CHTR2BPNMT | |
| Hydrochloric Acid SCHEMBL33527957 | 0.71 | PNMT (0.55) | CD44CD274HTR2CHTR2BPNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1483257-B1 | QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER LTD (GB) | 2006-09-13 | — | — | EP | disclosed |
| US-6936619-B2 | Cardiovascular disorders; antilipemic agents; sexual disorders | PFIZER, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| US-20040029859-A1 | Compounds useful in therapy | PFIZER INC. | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029859-A1 | Compounds useful in therapy | ADRA1D, HSD3B1, PTGER1 | CD44 4761/4885CD274 4606/4885HRH3 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.